All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

EHA 2024 abstracts: What’s hot in lymphoma and CLL?

Jun 10, 2024

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2024 Congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.

Indolent and mantle cell NHL

Hodgkin lymphoma

T-cell lymphoma

Aggressive B-NHL


Glofitamab plus gemcitabine and oxaliplatin (GLOFIT-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results of a global randomized phase III trial (STARGLO)


Feasibility and clinical efficacy of atezolizumab consolidation in high risk diffuse large B-cell lymphoma: final analysis of the HOVON 151


Englumafusp alfa (CD19/4-1BBL) combined with glofitamab is safe and shows high efficacy in patients with R/R aggressive B-NHL: final results of the dose-escalation part of phase1 trial BP41072


Biomarker-adapted treatment in high-risk large B-cell lymphoma: long-term follow-up of a NORDIC phase II trial


First data from subcutaneous epcoritamab+polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-R-CHP) for first-line diffuse large B-cell lymphoma (DLBCL): EPCORE NHL-5


TRANSCAR: A real-life outcome study of relapsed/refractory transformed indolent non-Hodgkin lymphoma in the context of CAR T-cells a DESCART analysis


Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by ASCT as second-line treatment in patients with R/R large B-cell lymphoma: 3-year follow-up of TRANSFORM


Efficacy and safety of zanubrutinib combined with R-CHOP regimen in the treatment of newly diagnosed diffuse large b-cell lymphoma with extranodal involvement: a prospective phase II trial in China


A phase II, single-arm, open-label study to evaluate the safety and efficacy of tafasitamab combined with lenalidomide in patients with relapsed/ refractory diffuse large B-cell lymphoma


Bruton tyrosine kinase inhibitors and chidamide-combined therapy in relapsed or refractory diffuse large B-cell lymphoma

Chronic lymphocytic leukemia (CLL)


Latest results from an ongoing first-in-human phase 1a/b study of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory CLL and other B-cell malignancies


Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (SONRO) in combination with zanubrutinib (ZANU) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses


Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study


Characteristics associated with response to lisocabtagene maraleucel (liso‑cel) in patients (pts) with R/R CLL/SLL: exploratory analyses from TRANSCEND CLL 004


Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17P) and/or TP53: preliminary results from SEQUOIA arm D


Minimal residual disease-guided combination of ibrutinib plus venetoclax compared to FCR in untreated patients with CLL of intermediate risk : interim results from the phase II FILO trial.


7-year update on a phase 2 trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL


Single-agent epcoritamab leads to deep responses in patients (pts) with Richter’s transformation (RT): primary results from the EPCORE CLL-1 trial


Combined pirtobrutinib, venetoclax, and obinutuzumab in first-line treatment of patients with chronic lymphocytic leukemia (CLL): a phase 2 trial


6-year time to next treatment (TTNT) extrapolation curve for GLOW study: first-line ibrutinib + venetoclax (I+V) offers long treatment-free period for elderly/unfit CLL patients


A phase II study of time-limited treatment with acalabrutinib plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia


Updated results of combination treatment with ibrutinib and venetoclax in patients with chronic lymphocytic leukemia and complex karyotype: 4-year follow-up

EHA 2024 top abstracts

To download this document, click below.

Download here

More about...

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox